#SPRY

6 days ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization ARS Pharmaceuticals (NASDAQ: SPRY) reported full-year 2025 revenue of $84.3M including $72.2M of U.S. net product revenue from neffy, and Q4 2025 revenue of $28.1M. Full-year SG&A was $230.1M and net loss was $171.3M. The company held $245.0M in cash and short-term investments at year-end and expects that cash to fund operations through anticipated cash-flow break-even. Commercial progress includes expanded payor discussions, a January 2026 DTC ad, salesforce growth to 150 reps in Q2 2026, and regulatory approvals in China, Australia and a CHMP positive opinion for EURneffy 1 mg.

#SPRY ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

www.stocktitan.net/news/SPRY/ars-pharmaceut...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

2 months ago

Is ARS Pharmaceuticals a buy? Roth Capital Markets analyst Kyle Bauser has reiterated a Buy rating and a 12-month price target of $30.00 on ARS Pharmaceuticals

Is ARS Pharmaceuticals a buy? Roth Capital Markets analyst Kyle Bauser reiterated a Buy rating and a 12-month price target of $30.00 on ARS Pharmaceuticals (ARS Pharmaceuticals Stock Quote, Chart, ...

#All #posts #American #Tech #Analysts #SPRY

Origin | Interest | Match

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis) neffy is the first epinephrine product approved for use out of a hospital setting in China for adults and children ( 30 kg) living with severe allergic reactions Pediatrix Therapeutics, which has a license from ARS Pharma to market neffy in China under the trade name 优敏速 ® , expects availability in

#SPRY neffy® (epinephrine nasal spray) Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions (anaphylaxis)

www.stocktitan.net/news/SPRY/neffy-epinephr...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray) ARS Pharmaceuticals (Nasdaq: SPRY) reported third quarter 2025 results and commercial progress for neffy® (epinephrine nasal spray). Q3 revenue was $32.5M, including $31.3M U.S. net product revenue; net loss was $51.2M (−$0.52/share). Cash, cash equivalents and short-term investments totaled $288.2M as of September 30, 2025, after a $100M draw on a $250M term loan facility; shares outstanding were 98,844,178. Commercial milestones: consumer awareness rose from ~20% to 56%, >18,000 HCPs prescribed neffy (an 86% increase), >6,500 schools enrolled, and real-world data (n=680) showed ~90% effective single-dose treatment rates.

#SPRY ARS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights for neffy® (epinephrine nasal spray)

www.stocktitan.net/news/SPRY/ars-pharmaceut...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray) ARS Pharma (Nasdaq: SPRY) launched Get neffy on Us on November 4, 2025, an integrated commercial program to expand access to neffy (epinephrine nasal spray).Key features: a free virtual prescriber visit taking 5–10 minutes, potential $0 co-pay for eligible commercially insured patients, and delivery to a pharmacy or home within 3–5 days. The company cites ~40 million people with severe allergies and survey interest of >70% in virtual prescribing. The program complements neffyInSchools, which has provided neffy to >6,600 schools across >20 states. More information is available at www.getneffy.com or 1-877-MY-NEFFY.

#SPRY ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)

www.stocktitan.net/news/SPRY/ars-pharma-lau...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

#SPRY ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results

www.stocktitan.net/news/SPRY/ars-pharmaceut...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

$250M Financing Deal: ARS Pharma's Needle-Free Allergy Treatment neffy Targets $2B Market Opportunity ARS Pharmaceuticals secures $250M loan facility, with initial $100M draw to accelerate neffy's commercial growth. Drug shows 93% patient acceptance rate, targeting $2B annual US epinephrine market.

#SPRY ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®

www.stocktitan.net/news/SPRY/ars-pharmaceut...

0 0 0 0

GetNews.me

@getnews-me.bsky.social

6 months ago

AI-Powered Prior Authorization Automates Up to 80% for Rehab Clinics

SPRY Therapeutics' AI Prior Authorization & Eligibility Solution can automate up to 80% of the workflow and processes 99% of eligibility files in under an hour. Read more: getnews.me/ai-powered-prior-authori... #spry #priorauthorization #rehab

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray) ARS Pharmaceuticals (NASDAQ: SPRY) reported strong Q2 2025 financial results, highlighting significant growth for neffy®, their needle-free epinephrine nasal spray. The company achieved $15.7 million in total revenue, including $12.8 million from U.S. neffy sales. Key commercial milestones include 93% commercial coverage and a 180% increase in prescription volumes from Q1 to Q2 2025.The company has expanded globally with EURneffy® approval in the UK and launch in Germany. Financial position remains strong with $240.1 million in cash and investments, supporting operations for at least three years despite a net loss of $44.9 million for the quarter. The company has initiated a Phase 2b trial for urticaria and expects additional regulatory approvals in Canada, Japan, Australia, and China by 2026.

#SPRY ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy® (epinephrine nasal spray)

www.stocktitan.net/news/SPRY/ars-pharmaceut...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

ARS Pharmaceuticals Q2 Earnings Call: Anaphylaxis Treatment Leader Reports Latest Financial Results Join ARS Pharmaceuticals' Q2 earnings call on Aug 13, 8:30 AM ET. Get insights on their anaphylaxis treatment progress and financial performance. Register now.

#SPRY ARS Pharmaceuticals Announces Conference Call and Webcast for its Second Quarter 2025 Financial Results

www.stocktitan.net/news/SPRY/ars-pharmaceut...

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) ARS Pharmaceuticals (NASDAQ:SPRY) has achieved a significant milestone as the UK's Medicines and Healthcare products Regulatory Agency (MHRA) approved EURneffy, the first needle-free adrenaline nasal spray for emergency treatment of allergic reactions. The approval covers adults and children weighing over 30 kg.The company's partnership with ALK-Abelló A/S includes a $145 million upfront payment and potential additional payments of up to $320 million in milestones, plus tiered double-digit royalties. The UK represents the largest market outside the US for adrenaline auto-injector sales. EURneffy's launch is expected in late Q3 2025.The product offers advantages including temperature stability up to 50°C and longer shelf life compared to auto-injectors. Additional regulatory approvals are anticipated in Canada, Japan, and Australia by end of 2025, with China following in 2026.

#SPRY EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

www.stocktitan.net/news/SPRY/eu-rneffy-adre...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

ARS Pharma Q1 Earnings: First Needle-Free Epinephrine Spray Hits $7.8M Revenue, 57% Insurance Coverage Q1 financial results reveal neffy's market traction with 5,000+ prescribing physicians and major insurance coverage wins. See full commercial launch metrics.

#SPRY ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

www.stocktitan.net/news/SPRY/ars-pharmaceut...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

ARS Pharmaceuticals Sets Q1 2025 Earnings Date: Key Updates Expected on Anaphylaxis Treatment Progress ARS Pharmaceuticals to discuss Q1 2025 performance and anaphylaxis treatment developments. Join May 14 at 8:30 AM ET to hear latest milestones. Get insights.

#SPRY ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

www.stocktitan.net/news/SPRY/ars-pharmaceut...

0 0 0 0

Seth V

@beernut1.bsky.social

10 months ago

a baby in a diaper is pointing at the camera while standing on a table . ALT: a baby in a diaper is pointing at the camera while standing on a table .

So #CityOfTheDead is an acting awful #Spry what w/ all the dancing & threats of being #TurnedOut for the Hotel staff, I really say they appear! #SpryAF #MutantFam #HorrorFam #TheLastDriveIn @shudder.bsky.social @darcythemailgirl.bsky.social @therealjoebob123.bsky.social @themutantfam.bsky.social

0 0 0 0

C. Oulens

@owlnsquirrels1111.bsky.social

11 months ago

old folks watch dry leaves in fall redolent of once spry limbs

#haikufeels #spry
#haikuchallenge #redolent

#Haiku #senryu #monoku

#blueskypoets #blueskypoetry
#poetrycommunity #poems
#poetry #writingcommunity
#writingprompts #writing #inspiration

29 0 0 0

Thomas Hill

@thomaserichill.bsky.social

11 months ago

prompt #spry

#haiku
#haikufeels (prompt source)

Squeak echoing leaps
Spry whispers weaving regime,
Nature’s healing sigh.

Art by Chat Smith AI Art using my haiku

Note: I derived my haiku from my VSS.